No Data
Stock market midday report: the chinext price index rose by 1.78%, with over 3000 stocks increasing. The pharmaceutical commerce concept leads the gains.
As of the midday close, the Shanghai Composite Index fell by 0.06%, the Shenzhen Component Index rose by 1.02%, and the chinext price index rose by 1.78%.
Yunnan Jianzhijia Health-chain (605266): The operation improved compared to the previous period and continued to promote structural optimization.
On the evening of October 29, the company released the 2024 third-quarter performance report, achieving revenue of 6.735 billion yuan, a year-on-year increase of 3.63%, and achieving a net income attributable to the parent company of 0.101 billion yuan, a year-on-year decrease of 63.
Express News | yunnan jianzhijia health-chain: The company's current operational situation is normal.
yunnan jianzhijia health-chain (605266) 2024 Third Quarter Report Review: Short-term profit pressure, focusing on cost control and efficiency improvement.
Items: The company announced that in the third quarter of 24, the revenue, net profit attributable to the mother, and non-net profit were 6.74, 0.1, 0.1 billion yuan, with year-on-year changes of +3.6%, -63.8%, and -64.3% respectively. Among them, 3Q24 revenue, net profit attributable to the mother
yunnan jianzhijia health-chain (605266.SH): Cumulatively repurchased 0.48% of the company's shares.
Golden Roll November 1st | Yunnan Jianzhijia Health-chain (605266.SH) announced that, as of October 31, 2024, the company has repurchased a total of 748,000 shares of the company through the Shanghai Stock Exchange through centralized competitive trading, accounting for 0.48% of the company's current total share capital of 156,660,808 shares. The lowest price of the repurchase transaction is 18.21 yuan/share, the highest price is 23.04 yuan/share, and the total amount of funds used is 16.3477 million yuan.
Yunnan Jianzhijia Health-Chain (605266): Stable income growth, expanding stores outward.
Event: The company released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 6.74 billion yuan (+3.6%); net income attributable to mother 0.1 billion yuan (-63.8%); non-net income attributable to mother 0.1 billion.
No Data
No Data